{"blog": [], "keywords": [{"value": "Drugs (Pharmaceuticals)", "name": "subject", "rank": "1", "is_major": "Y"}, {"value": "Multiple Sclerosis", "name": "subject", "rank": "2", "is_major": "Y"}, {"value": "Generic Brands and Products", "name": "subject", "rank": "3", "is_major": "Y"}, {"value": "Momenta Pharmaceuticals Inc", "name": "organizations", "rank": "4", "is_major": "Y"}, {"value": "Sandoz International GmbH", "name": "organizations", "rank": "5", "is_major": "Y"}, {"value": "Food and Drug Administration", "name": "organizations", "rank": "6", "is_major": "Y"}, {"value": "Teva Pharmaceutical Industries Ltd", "name": "organizations", "rank": "7", "is_major": "Y"}], "web_url": "http://www.nytimes.com/2015/04/17/business/generic-version-of-copaxone-multiple-sclerosis-drug-is-approved.html", "document_type": "article", "byline": {"person": [{"lastname": "POLLACK", "firstname": "Andrew", "role": "reported", "organization": "", "rank": 1}], "original": "By ANDREW POLLACK"}, "type_of_material": "News", "multimedia": [], "section_name": "Business Day", "word_count": "862", "source": "The New York Times", "subsection_name": null, "lead_paragraph": "About 10 drugs are now approved to treat multiple sclerosis, and their prices are rising sharply. The generic Copaxone could help keep prices of all the drugs in check.", "pub_date": "2015-04-17T00:00:00Z", "news_desk": "Business", "headline": {"print_headline": "Generic Version of Copaxone, Multiple Sclerosis Drug, Is Approved", "main": "Generic Version of Copaxone, Multiple Sclerosis Drug, Is Approved"}, "print_page": "3", "snippet": "About 10 drugs are now approved to treat multiple sclerosis, and their prices are rising sharply. The generic Copaxone could help keep prices of all the drugs in check.", "_id": "5530051838f0d847eef0f488", "slideshow_credits": null, "abstract": "Food and Drug Admin approves first generic substitute for multiple sclerosis drug Copaxone, the biggest-selling product for Teva Pharmaceutical Industries; generic, developed by Sandoz and Momenta Pharmaceuticals, could introduce competition for drug that costs some $60,000 per year."}